Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
Rand A Alattar, Shiema Abdalla, Tasneem Abdallah, Rashid Kazman, Aseelah Qadmour, Tawheeda Ibrahim, Bassem Alhariri, Shahd H Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi, Fatma Ben Abid, Joanne Daghfal, Ali Eldeeb, Kinda Shukri, Ahmed Elsayed, Fatima Rustom, Musaed Alsamawi, Alaaeldin Abdelmajid, Miguel A P Basulto, Armando A R Cobian, Mohamed Abukhattab, Abdullatif Alkhal, Muna A Almaslamani, Ali S Omrani
Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Ethical approval The study was approved by the Institutional Review Board at Hamad Medical Corporation (MRC-01-20-994), with a waiver of informed consent.
Funding The publication of this article was funded by the Qatar National Library. J o u r n a l P r e -p r o o f
Declaration of Interest
None
References
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med,
doi:10.1056/NEJMoa2007764Cevik, Kuppalli, Kindrachuk, Peiris, Virology, transmission, and pathogenesis of SARS-CoV-2, BMJ,
doi:10.1136/bmj.m3862Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19, Antimicrob Agents Chemother,
doi:10.1128/AAC.01897-20Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci,
doi:10.2183/pjab.93.027Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis,
doi:10.1093/cid/ciaa1176J O U R N A L P R E, -p r o o f
Kumagai, Murakawa, Hasunuma, Aso, Yuji et al., Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults, Int J Clin Pharmacol Ther,
doi:10.5414/cp202388Lagocka, Dziedziejko, Kłos, Pawlik, Favipiravir in Therapy of Viral Infections, J Clin Med,
doi:10.3390/jcm10020273Manabe, Kambayashi, Akatsu, Kudo, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis,
doi:10.1186/s12879-021-06164-xÖzlüşen, Kozan, Akcan, Kalender, Yaprak et al., Effectiveness of favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis,
doi:10.1007/s10096-021-04307-1{ 'indexed': {'date-parts': [[2022, 8, 28]], 'date-time': '2022-08-28T00:12:51Z', 'timestamp': 1661645571683},
'reference-count': 11,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2022, 8, 1]],
'date-time': '2022-08-01T00:00:00Z',
'timestamp': 1659312000000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2022, 8, 22]],
'date-time': '2022-08-22T00:00:00Z',
'timestamp': 1661126400000},
'content-version': 'vor',
'delay-in-days': 21,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2022, 8]]},
'DOI': '10.1016/j.jiph.2022.08.011',
'type': 'journal-article',
'created': {'date-parts': [[2022, 8, 27]], 'date-time': '2022-08-27T23:56:42Z', 'timestamp': 1661644602000},
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched '
'Cohort Study',
'prefix': '10.1016',
'author': [ {'given': 'Rand A.', 'family': 'Alattar', 'sequence': 'first', 'affiliation': []},
{'given': 'Shiema', 'family': 'Abdalla', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tasneem', 'family': 'Abdallah', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rashid', 'family': 'Kazman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Aseelah', 'family': 'Qadmour', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tawheeda', 'family': 'Ibrahim', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bassem', 'family': 'Alhariri', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shahd H.', 'family': 'Shaar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Abeer', 'family': 'Bajwa', 'sequence': 'additional', 'affiliation': []},
{'given': 'Abeir', 'family': 'Alimam', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rabia', 'family': 'Qazi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fatma', 'family': 'Ben Abid', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joanne', 'family': 'Daghfal', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ali', 'family': 'Eldeeb', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kinda', 'family': 'Shukri', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ahmed', 'family': 'Elsayed', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fatima', 'family': 'Rustom', 'sequence': 'additional', 'affiliation': []},
{'given': 'Musaed', 'family': 'Alsamawi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alaaeldin', 'family': 'Abdelmajid', 'sequence': 'additional', 'affiliation': []},
{'given': 'Miguel A.P.', 'family': 'Basulto', 'sequence': 'additional', 'affiliation': []},
{'given': 'Armando A.R.', 'family': 'Cobian', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mohamed', 'family': 'Abukhattab', 'sequence': 'additional', 'affiliation': []},
{'given': 'Abdullatif', 'family': 'Alkhal', 'sequence': 'additional', 'affiliation': []},
{'given': 'Muna A.', 'family': 'Almaslamani', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ali S.', 'family': 'Omrani', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.jiph.2022.08.011_bib1',
'doi-asserted-by': 'crossref',
'first-page': '449',
'DOI': '10.2183/pjab.93.027',
'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase',
'volume': '93',
'author': 'Furuta',
'year': '2017',
'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib2',
'doi-asserted-by': 'crossref',
'first-page': '2575',
'DOI': '10.1007/s10096-021-04307-1',
'article-title': 'Effectiveness of favipiravir in COVID-19: a live systematic review',
'volume': '40',
'author': 'Özlüşen',
'year': '2021',
'journal-title': 'Eur J Clin Microbiol Infect Dis'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib3',
'doi-asserted-by': 'crossref',
'first-page': '1813',
'DOI': '10.1056/NEJMoa2007764',
'article-title': 'Remdesivir for the Treatment of Covid-19 — Final Report',
'volume': '383',
'author': 'Beigel',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib4',
'doi-asserted-by': 'crossref',
'first-page': '489',
'DOI': '10.1186/s12879-021-06164-x',
'article-title': 'Favipiravir for the treatment of patients with COVID-19: a systematic '
'review and meta-analysis',
'volume': '21',
'author': 'Manabe',
'year': '2021',
'journal-title': 'BMC Infect Dis'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib5',
'doi-asserted-by': 'crossref',
'first-page': 'm3862',
'DOI': '10.1136/bmj.m3862',
'article-title': 'Virology, transmission, and pathogenesis of SARS-CoV-2',
'volume': '371',
'author': 'Cevik',
'year': '2020',
'journal-title': 'BMJ'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib6',
'doi-asserted-by': 'crossref',
'first-page': '273',
'DOI': '10.3390/jcm10020273',
'article-title': 'Favipiravir in Therapy of Viral Infections',
'volume': '10',
'author': 'Lagocka',
'year': '2021',
'journal-title': 'J Clin Med'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib7',
'first-page': '64',
'article-title': 'A Prospective, Randomized, Open-Label Trial of Early versus Late '
'Favipiravir Therapy in Hospitalized Patients with COVID-19',
'author': 'Doi',
'year': '2020',
'journal-title': 'Antimicrob Agents Chemother'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib8',
'first-page': '693',
'article-title': 'Collaborative Group. Dexamethasone in Hospitalized Patients with '
'Covid-19',
'volume': '384',
'author': 'RECOVERY',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib9',
'doi-asserted-by': 'crossref',
'first-page': '1637',
'DOI': '10.1016/S0140-6736(21)00676-0',
'article-title': 'Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): '
'a randomised, controlled, open-label, platform trial',
'volume': '397',
'author': 'RECOVERY Collaborative Group',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib10',
'doi-asserted-by': 'crossref',
'first-page': '531',
'DOI': '10.1093/cid/ciaa1176',
'article-title': 'AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim '
'Results of a Phase II/III Multicenter Randomized Clinical Trial',
'volume': '73',
'author': 'Ivashchenko',
'year': '2020',
'journal-title': 'Clin Infect Dis'},
{ 'key': '10.1016/j.jiph.2022.08.011_bib11',
'doi-asserted-by': 'crossref',
'first-page': '866',
'DOI': '10.5414/CP202388',
'article-title': 'Lack of effect of favipiravir, a novel antiviral agent, on QT interval '
'in healthy Japanese adults',
'volume': '53',
'author': 'Kumagai',
'year': '2015',
'journal-title': 'Int J Clin Pharmacol Ther'}],
'container-title': 'Journal of Infection and Public Health',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S187603412200212X?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S187603412200212X?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2022, 8, 27]],
'date-time': '2022-08-27T23:56:51Z',
'timestamp': 1661644611000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S187603412200212X'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 8]]},
'references-count': 11,
'alternative-id': ['S187603412200212X'],
'URL': 'http://dx.doi.org/10.1016/j.jiph.2022.08.011',
'relation': {},
'ISSN': ['1876-0341'],
'subject': [ 'Infectious Diseases', 'Public Health, Environmental and Occupational Health',
'General Medicine'],
'container-title-short': 'Journal of Infection and Public Health',
'published': {'date-parts': [[2022, 8]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a '
'Propensity Score-matched Cohort Study',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Journal of Infection and Public Health',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.jiph.2022.08.011',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin '
'Abdulaziz University for Health Sciences.',
'name': 'copyright',
'label': 'Copyright'}]}
